Skip to content

May 25 - 27, 2022


To be announced


All Times Eastern Standard Time

Tuesday, May 24



DAY 1 — Wednesday, May 25


8:00am - 5:00pm

One-on-One Partnering

8:00am - 5:00pm

• Conference Welcome
• Keynote presented by SVB Securities

Please join us for an interactive discussion regarding observations on the financing and strategic environment for “breakthrough” medical technology companies in a 2022 world that has evolved considerably from what we had become accustomed to in recent years. 

Jed Cohen, Senior Managing Director Medical Technology Investment Banking, SVB Securities

Room A – Biopharma & Diagnostics
Room B – Medtech & Healthtech

In 2017 Avanos Medical was formed after completing its spinoff from consumer giant Kimberly Clark and divesting its Surgical & Infection Prevention business . After five plus years of acquisitions, responses to unmet industry needs and the needs to heighten focus on commercial execution and increase production in the midst of the global COVID-19 pandemic, Avanos is now an industry leading pure play medical device company.


What does a successful, seismic shift in healthcare business strategy and execution take? What can it mean for life science innovators and their investors? What made it possible?


For investors – How is Avanos delivering on its growth potential? 

For both early and later stage companies? How is Avanos leveraging Open Innovation and M+A to help drive our growth objectives?


Find out during Avanos CEO Joe Woody’s keynote at Southeast Life Science’s AdvanSE 2022.

Room A – 1:30 – 2:30
Industry’s Best Practices to Reach Commercialization Sooner

These presentations target the executive decision-maker, ideally ahead or during early project concept and planning phases.

Quality Risk Management

Traditional start-up times are no longer acceptable. New norms include collaborative, project advancing approaches throughout the project life cycle. Critical to the emerging sector, early communication with strategic partners is essential to reduce time to market, time to patient, in a safe, quality-minded manner. Existing companies also benefit as a means to depart from the traditional, antiquated methods in favor of modern approaches.

Operational Readiness

Turning a capital project or technology transfer into successful operations requires focused execution of a structured, multi-workstream plan.  Your ability to define clear objectives and establish ownership in each department and workstream will either propel your site to success or leave you stranded short of your operational goals.


2:30-3:00 – Beyond Grants & VCs: Funding Options for Early Stage Companies


Bill Dull, Partner/ COO, BioTech Exec

Richard Otto, Founding Partner, Forest Partners

Donna Edmonds, CEO, BRAINBox Solutions Inc

Russell Allen (moderator) , CEO BioTech Exec


Room B – 1:30 – 2:15

Incubators: More than just an office.

Moderator: Paul Gianneschi, Managing Principal & Founder, Hatch Medical

John Flavin, Founder & CEO- Portal Innovations

Alex Cate, Director of Entrepreneurship Programs, Hudson Alpha


2:15- 3:00 – AgTech is Life Science: A Primer

Moderator: Tim Martin, Senior Licensing Associate, North Carolina State University

Chris Rhodes, Director of Industry Partnerships & Project-Based Learning, University of Georgia


Nick Schroer, Vice President, Trailhead Capital


Annette Kleiser, CEO, Dalan Animal Health

Kickoff Keynote

SE Color Keynote Panel – Scaling and Growing: The Need for Diversity in Health Innovations


  • Dr. Yolanda Wimberly, Grady Health System
  • Ibraheem Badejo,  Johnson & Johnson
  • Burunda Prince, RCIE
  • Dr. Jayne Morgan, Piedmont (moderator)

Women@SLS Panel

  • Marta New, Radyus Research 
  • Kathy Lee -Sepsick, Femasys
  • Tiffany Wilson, Moderator, University City Science Center

Enjoy the many opportunities for dining at the Avalon! 

DAY 2 — Thursday, May 26


8:00am - 5:00pm

One-on-One Partnering

8:00am - 5:00pm

What Does Judo Have to Do with Supply Chain, Manufacturing and Life Science Investing?


The Smart Money in Life Science Investing is Smart Everywhere, Including the Supply Chain and Manufacturing.

The Pandemic taught us that “just in time” and “lean” processes are easily and thoroughly disrupted when multiple environmental changes take place. 


If a product or technology involves novelty or materials and components critical to the product but not easily acquired or produced, that has the potential to extend development timelines, delay manufacturing transfer, time to market and ultimately adds risk that is ultimately unacceptable for investors. For example: distribution of Pfizer’s Covid vaccine demanded temperatures that required liquid oxygen for transport, it was a huge issue.


How do you reduce that risk? Make sure your team has the right expertise in manufacturing and supply chain then learn to play Judo with suppliers.


What attendees will learn

  • Where are the supply chain and manufacturing landmines that generate risk investors may find unacceptable?
  • How can investors mitigate those risks and when?
  • At what point in the innovation process does manufacturing strategy need to enter the conversation and why?


Mike Fisher, Director of Product Development, GCMI

Samir Merchant, Director of Global Procurement, Avanos

Robin Pennisi, Director of Supply Chain Programs, Avanos

Paul Snyder, VP, Healthcare, Write2Market (moderator)


Life Sciences to the Cellular Level: A Chat with Mason Chilmonczyk, CEO and Co-Founder, Andson Biotech and Jason Rupp


  • South Carolina: David Stefanich, CEO, Rymedi
  • Alabama: Robert Agnew, CEO, TruSpin

Room A – Biopharma & Diagnostics 
Room B – Medtech & Healthtech

Douglas E. Kelly, MD, MBA
Chief Scientist, Center for Devices and Radiological Health, U.S. Food and Drug Administration

Doug Kelly, MD joined the FDA in 2020 after a 30-year life sciences venture capital career starting, financing, growing and exiting companies spanning biotech, medical devices, robotics, laboratory tools, healthcare IT, ADME/Tox simulation and clinical trial software. At CDRH, Doug is the interface between the FDA and patient and physician groups, payors, industry, academia, innovators, investors, and other agencies and governments. His focus is on creating a more vibrant and sustainable medtech ecosystem, to bring new innovations to patients faster to relieve suffering, especially in unserved and underserved populations.

The gist: Accelerating early-stage medtech. FDA’s TAP program for Breakthrough-Designated products combines early stakeholder input, strategic advisory services, real-time communications and radical transparency to dramatically reduce the risk, time and cost of early-stage medtech while producing more financially sustainable companies and better characterized, safer and more effective products.

Doug received his BA in Biochemistry and Cell Biology with honors from University of California, San Diego, his MD from the Albert Einstein College of Medicine, and his MBA at the Stanford University Graduate School of Business. In addition to lecturing at the Stanford GSB and Medical School, he conceived of and taught the class “Financing The Start-up,” for over a decade the Stanford’s Department of Continuing Education biggest and most popular class.

Room A – Biopharma/diagnostics (3 VCs/3 portfolio CEOs)

Room B – Devices/Three Health IT/Innovative Delivery Topics (3 VCs/3 portfolio CEOs)

Room A – Biopharma/diagnostics (3 VCs/3 portfolio CEOs)

Room B – Devices/Three Health IT/Innovative Delivery Topics (3 VCs/3 portfolio CEOs)

Top Four Companies from PitchRounds

DAY 3 — Friday, May 27

One-on-One Partnering

8:00am - 12:00pm


  • Rachel Lane, CEO, Alabama Bio
  • Maria Thacker, President & CEO, Georgia Bio/Center for Global Health Innovation
  • Abby Trotter, Executive Director, Life Science TN
  • Laura Gunter, President, NCBIO 
  • James Chappell, President & CEO, SCBio
  • John Newby, CEO, VirginiaBio